SwePub
Tyck till om SwePub Sök här!
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:DiVA.org:uu-350272"
 

Sökning: onr:"swepub:oai:DiVA.org:uu-350272" > Long-term safety an...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00005106naa a2200625 4500
001oai:DiVA.org:uu-350272
003SwePub
008180514s2018 | |||||||||||000 ||eng|
009oai:prod.swepub.kib.ki.se:137784357
009oai:gup.ub.gu.se/260993
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-3502722 URI
0247 a https://doi.org/10.1007/s10549-017-4599-42 DOI
0247 a http://kipublications.ki.se/Default.aspx?queryparsed=id:1377843572 URI
0247 a https://gup.ub.gu.se/publication/2609932 URI
040 a (SwePub)uud (SwePub)kid (SwePub)gu
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Matikas, Alexiosu Karolinska Institutet4 aut
2451 0a Long-term safety and survival outcomes from the Scandinavian Breast Group 2004-1 randomized phase II trial of tailored dose-dense adjuvant chemotherapy for early breast cancer
264 c 2017-11-30
264 1b SPRINGER,c 2018
338 a electronic2 rdacarrier
520 a Although adjuvant polychemotherapy improves outcomes for early breast cancer, the significant variability in terms of pharmacokinetics results in differences in efficacy and both short and long-term toxicities. Retrospective studies support the use of dose tailoring according to the hematologic nadirs. The SBG 2004-1 trial was a randomized feasibility phase II study which assessed tailored dose-dense epirubicin and cyclophosphamide (EC) followed by docetaxel (T) (group A), the same regimen with fixed doses (group B) and the TAC regimen (group C). Women aged 18-65 years, ECOG PS 0-1 with at least one positive axillary lymph node were randomized 1:1:1. The primary endpoint of the study was the safety and feasibility of the treatment. Toxicity was graded according to CTC-AE version 3.0. The design and short-term toxicity have been previously published. Here, we report safety and efficacy data after 10 years of follow-up. A total of 124 patients were included in the study. After a median follow-up of 10.3 years, the probability for 10-year survival was 78.5, 75.1, and 63.4% and for relapse free survival 64.1, 71.0, and 59.5% for groups A, B, and C, respectively. There were no cases of clinically diagnosed cardiotoxicity or hematologic malignancies. No patient was lost to follow-up. In this randomized phase II trial, tailored dose adjuvant chemotherapy was feasible, without an increased risk for long-term adverse events after a median follow-up of 10 years.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng
653 a Adjuvant chemotherapy
653 a Breast cancer
653 a Dose-dense
653 a Randomized
653 a Tailored dose
7001 a Margolin, Sarau Karolinska Institutet4 aut
7001 a Hellström, Matsu Karolinska Univ Hosp, Radiumhemmet, Dept Oncol, Stockholm, Sweden.4 aut
7001 a Johansson, Hemmingu Karolinska Institutet4 aut
7001 a Bengtsson, Nils-Olofu Norrland Univ Hosp, Umea, Sweden.4 aut
7001 a Karlsson, Lenau Cty Hosp, Sundsvall, Sweden.4 aut
7001 a Edlund, Peru Gavle Cent Hosp, Gavle, Sweden.4 aut
7001 a Karlsson, Per,d 1963u Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för onkologi,Institute of Clinical Sciences, Department of Oncology4 aut0 (Swepub:gu)xkperd
7001 a Lidbrink, Elisabetu Karolinska Univ Hosp, Radiumhemmet, Dept Oncol, Stockholm, Sweden.4 aut
7001 a Linderholm, Barbro,d 1959u Gothenburg University,Göteborgs universitet,Karolinska Institutet,Institutionen för kliniska vetenskaper, Avdelningen för onkologi,Institute of Clinical Sciences, Department of Oncology4 aut0 (Swepub:gu)xlibar
7001 a Lindman, Henriku Uppsala universitet,Experimentell och klinisk onkologi4 aut0 (Swepub:uu)henrlind
7001 a Malmstrom, Peru Skane Univ Hosp, Dept Oncol & Radiat Phys, Lund, Sweden.4 aut
7001 a Villman, Kennethu Orebro Univ Hosp, Orebro, Sweden.4 aut
7001 a Foukakis, Theodorosu Karolinska Institutet4 aut
7001 a Bergh, Jonasu Karolinska Institutet4 aut
7102 a Karolinska Institutetb Karolinska Univ Hosp, Radiumhemmet, Dept Oncol, Stockholm, Sweden.4 org
7730 t Breast Cancer Research and Treatmentd : SPRINGERg 168:2, s. 349-355q 168:2<349-355x 0167-6806x 1573-7217
8564 u https://doi.org/10.1007/s10549-017-4599-4y Fulltext
8564 u https://uu.diva-portal.org/smash/get/diva2:1205402/FULLTEXT01.pdfx primaryx Raw objecty fulltext:print
8564 u https://link.springer.com/content/pdf/10.1007%2Fs10549-017-4599-4.pdf
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-350272
8564 8u https://doi.org/10.1007/s10549-017-4599-4
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:137784357
8564 8u https://gup.ub.gu.se/publication/260993

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy